terfenadine

E850017

Terfenadine is a withdrawn second-generation antihistamine formerly used to treat allergy symptoms but discontinued due to its risk of causing serious cardiac arrhythmias.

All labels observed (1)

Label Occurrences
terfenadine canonical 1

How this entity was disambiguated

Statements (50)

Predicate Object
instanceOf H1 receptor antagonist ⓘ
piperidine derivative ⓘ
second-generation antihistamine ⓘ
withdrawn drug ⓘ
actsOn histamine H1 receptor ⓘ
affectsIonChannel hERG potassium channel ⓘ
belongsToATCClass R06AX12 ⓘ
contraindicatedWith CYP3A4 inhibitors ⓘ
clarithromycin ⓘ
erythromycin ⓘ
grapefruit juice ⓘ
itraconazole ⓘ
ketoconazole ⓘ
crossesBloodBrainBarrier minimally ⓘ
developedBy Marion Merrell Dow ⓘ
hasActiveMetabolite fexofenadine ⓘ
hasAdverseEffect cardiac arrhythmia ⓘ
dizziness ⓘ
dry mouth ⓘ
headache ⓘ
palpitations ⓘ
sedation (low incidence) ⓘ
syncope ⓘ
hasBioavailability low due to first-pass metabolism ⓘ
hasCASNumber 50679-08-8 ⓘ
hasDrugBankID DB00342 ⓘ
hasIUPACName (±)-4-[1-(4-tert-butylphenyl)-4-(hydroxydiphenylmethyl)piperidin-4-ylidene]butanoic acid ⓘ
hasLogP high lipophilicity ⓘ
hasMeltingPoint 150-153 °C (approximate) ⓘ
hasMolecularFormula C32H41NO2 ⓘ
hasPharmacologicalEffect anti-allergic effect ⓘ
antihistamine effect ⓘ
hasProteinBinding high ⓘ
hasPubChemCID 5405 ⓘ
hasRisk QT interval prolongation ⓘ
sudden cardiac death ⓘ
torsades de pointes ⓘ
ventricular arrhythmia ⓘ
hasUNIIs 0H73WJJ391 ⓘ
introducedIn 1980s ⓘ
isProdrugOf fexofenadine ⓘ
metabolizedBy CYP3A4 ⓘ
routeOfAdministration oral ⓘ
usedFor allergic rhinitis ⓘ
chronic idiopathic urticaria ⓘ
seasonal allergic rhinitis ⓘ
withdrawnFromMarketIn European Union ⓘ
United States ⓘ
withdrawnIn 1990s ⓘ
withdrawnReason risk of serious cardiac arrhythmias ⓘ

How these facts were elicited

Referenced by (1)

Full triples — surface form annotated when it differs from this entity's canonical label.

CYP2J2 → metabolizes → terfenadine ⓘ